secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126240
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics reports Q4 net loss of $9.1M; announces up to $1.085B Chugai collaboration and $60.3M placement
--------------------------------------------------------------------------------

- Collaboration with Chugai for up to $1.085B to develop oral therapy using RaniPill; Chugai may expand to 5 additional targets.
- Raised $60.3M via oversubscribed private placement led by Samsara BioCapital, including $6.0M debt conversion.
- Initiated Phase 1 study of RT-114 (oral GLP-1/GLP-2 dual agonist) via RaniPill for obesity in December 2025.
- Cash and equivalents $49.7M as of Dec 31, 2025; expected to fund operations into Q4 2027, including Chugai milestone.
- Net loss for FY2025 was $41.0M, narrowed from $56.6M in FY2024; R&D expenses decreased 24% to $20.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/0001193125-26-126240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/rani-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer